StemCell Therapy

NORTH CHICAGO, Ill., Nov. 5, 2020 /PRNewswire/ --AbbVie (NYSE: ABBV) announced that it will present blood cancer data from nearly 40 abstracts, including 10 oral presentations, across 11 cancer types during the upcoming virtual American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8.

"We are steadfast in our commitment to advancing discovery, innovation and care for people with blood cancers," said Mohamed Zaki, M.D., Ph.D, vice president and global head of oncology development, AbbVie. "We are looking forward to sharing findings from our expanding hematology oncology portfolio and continued research and treatment advances during the ASH annual meeting."

AbbVie will present updated results from the CAPTIVATE study, evaluating disease-free survival in previously untreated patients with chronic lymphocyctic leukemia (CLL)/small lymphocytic leukemia (SLL) who received an ibrutinib (IMBRUVICA) + venetoclax (VENCLEXTA/ VENCLYXTO) combination regimen. As well, an update on a 5-year analysis of the MURANO study in a subset of relapsed/refractory CLL patients following venetoclax-(VENCLEXTA/ VENCLYXTO) rituximab therapy and 8-year follow-up ibrutinib (IMBRUVICA) data in high-risk patients with CLL (RESONATE-2 and iLLUMINATE) will be presented. AbbVie's new partners, Genmab and I-Mab will offer data from recently announced collaborations.

Details about presentations are as follows:

Abstract

Presentation Details

All times CT

Ibrutinib

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Session 642. CLL: Therapy, excluding TransplantationSaturday, December 5Session: 9:30 a.m. - 11:00 a.m.Oral Presentation: 11:30 a.m.

Five-Year Follow-Up of Ibrutinib Plus Rituximab vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE Study

Session 623. Mantle Cell, Follicular, and Other Indolent B-Cell LymphomaClinical Studies: Clinical studies in Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell LeukemiaSunday, December 6Session: 9:30 a.m. - 11:00 a.m.Oral Presentation: 11:30 a.m.

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib (Ibr)

Session 642. CLL: Therapy, excluding Transplantation: Poster II

Sunday, December 6

Outcomes of First-Line Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features With Up To 6.5 Years Follow-Up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Session 642. CLL: Therapy, excluding Transplantation: Poster IISunday, December 6

Long-Term Efficacy of First-line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

Session 642. CLL: Therapy, excluding Transplantation: Poster II

Sunday, December 6

Real-World Prognostic Biomarker Testing, Treatment Patterns and Dosing Among 1461 Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the informCLL Prospective Observational Registry

Session 642. CLL: Therapy, excluding Transplantation: Poster IIMonday, December 7,Session: 7:00 a.m. 8:30 a.m.Oral Presentation: 10:15 a.m.

Ibrutinib Plus Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 SYMPATICO Study

Session 623. Mantle Cell, Follicular, and Other Indolent B-Cell LymphomaClinical Studies: Poster III

Monday, December 7

Long-Term Follow-Up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrm's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE Trial

Session 623. Mantle Cell, Follicular, and Other Indolent B-Cell LymphomaClinical Studies: Poster IIIMonday, December 7

Venetoclax in Acute Myeloid Leukemia (AML)

Venetoclax Crosses the Blood Brain Barrier: A Pharmacokinetic Analysis of the Cerebrospinal Fluid in Pediatric Leukemia Patients

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Saturday, December 5

Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogenous Genomic Profiles

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I

Saturday, December 5

Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Saturday, December 5

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Session 613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies

Sunday, December 6

Session: 9:00 a.m. - 5:30 p.m.

Oral Presentation: 4:45 p.m.

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Session 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches

Sunday, December 6

Session: 9:00 a.m. - 5:30 p.m.

Oral Presentation: 12:15 p.m.

Cytopenia Management in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine in the VIALE-A Study

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster II

Sunday, December 6

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations vs Other Therapies: Results from the AML Real World EvidenCe (ARC) Initiative

Session 906. Outcomes ResearchMalignant Conditions (Myeloid Disease): Poster II

Sunday, December 6

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster IISunday, December 6

Real-World Treatment Patterns and Clinical Outcomes in Unfit Patients with AML Receiving First-Line Systemic Treatment or Best Supportive Care (CURRENT): Final Analysis

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

Sunday, December 6

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) REVIVE Study

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Monday, December 7

CYP3A Inhibitors and Impact of These Agents on Outcomes in Patients with Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine on the VIALE-A Study

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III

Monday, December 7

Venetoclax in Acute Lymphoblastic Leukemia (ALL)

Venetoclax and Navitoclax in Pediatric Patients With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Session 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Targeted Therapies

Sunday, December 6

Session: 9:00 a.m. - 5:30 p.m.

Oral Presentation: 4:30 p.m.

Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogenous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

Session 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III

Monday, December 7

Venetoclax in Chronic Lymphocytic Leukemia (CLL)

Five-Year Analysis of MURANO Study Demonstrates Enduring uMRD in a Subset of Relapsed/Refractory (R/R) CLL Patients Following Fixed Duration Venetoclax-Rituximab Therapy

Session 642. CLL: Therapy, excluding Transplantation

Saturday, December 5

Session: 9:00 a.m.- 5:30 p.m.Oral Presentation: 12:00 p.m.

Clonal Dynamics After Venetoclax-Obinutuzumab Therapy: Novel Insights From the Randomized, Phase 3 CLL14 Trial

Session 642. CLL: Therapy, excluding Transplantation

Saturday, December 5

Session: 9:00 a.m. - 5:30 p.m.

Oral Presentation: 12:30 p.m.

Characteristics and Outcome of Patients with Chronic Lymphocytic Leukaemia and Partial Response to Venetoclax-Oinutuzumab

Session 642. CLL: Therapy, excluding Transplantation: Poster I

Saturday, December 5

Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated With Venetoclax in the Clinical and Post-Marketing Settings

Session 642. CLL: Therapy, excluding Transplantation: Poster II

Sunday, December 6

Efficacy of Subsequent Novel Targeted Therapies, Including Repeat Venetoclax-Rituximab (VenR), in Patients with Relapsed/Refractory CLL Previously Treated With VenR in the MURANO Study

Session 642. CLL: Therapy, excluding Transplantation: Poster III

Monday, December 7

Visit link:
AbbVie to Highlight Blood Cancer Leadership and Advancing Oncology Pipeline at the ASH 62ND Annual Meeting - WFMZ Allentown

This entry was posted on November 5, 2020 at 9:52 am and is filed under Integrative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |